UCSF Dermatology Grand Rounds - 3 April 2024
Wednesday, April 03 at 8:10 am
-
10:15 am
Add to Calendar
2024-04-03 15:10:00
2024-04-03 17:15:00
UCSF Dermatology Grand Rounds - 3 April 2024
GRAND ROUNDS AND PATIENT VIEWING
Opportunities and Challenges in the Treatment of Human Papillomavirus InfectionCarrie Kovarik, MD, Professor, Dermatology, Dermatopathology, Infectious Diseases, University of Pennsylvania, Philadelphia, PAObjectives:1. Determine treatment options for challenging cases of Human Papillomavirus (HPV) on the skin and mucous membranes
2. Understand when to consider malignancy in cases of HPV and how to work with other specialties to optimize treatment
Speaker Disclosures: Carrie Kovarik, MD has stated that she has no financial relationships to disclose.
Moderator Disclosures: Anna Haemel, MD has disclosed that she is an advisor or reviewer for CSL Behring, a consultant for Guidepoint LLC and receives a research grant from Priovant.
Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.
1600 Divisadero Street
Herbst Hall Auditorium
San Francisco, CA 94115
United States
View on Map
Department Of Dermatology
Laura.Harrison@ucsf.edu
America/Los_Angeles
public
1600 Divisadero Street
Herbst Hall Auditorium
San Francisco, CA 94115
United States
View on Map
GRAND ROUNDS AND PATIENT VIEWING
Opportunities and Challenges in the Treatment of Human Papillomavirus Infection
Carrie Kovarik, MD, Professor, Dermatology, Dermatopathology, Infectious Diseases, University of Pennsylvania, Philadelphia, PA
Objectives:
1. Determine treatment options for challenging cases of Human Papillomavirus (HPV) on the skin and mucous membranes
2. Understand when to consider malignancy in cases of HPV and how to work with other specialties to optimize treatment
Speaker Disclosures: Carrie Kovarik, MD has stated that she has no financial relationships to disclose.
Moderator Disclosures: Anna Haemel, MD has disclosed that she is an advisor or reviewer for CSL Behring, a consultant for Guidepoint LLC and receives a research grant from Priovant.
Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.